Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.49 |
| ▸ | NPY4R | P50391 | 9/20 | 0.48 |
| ▸ | NPY1R | P25929 | 6/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | GLP1R | P43220 | 1/20 | 0.46 |
| ▸ | SCTR | P47872 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.45 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526513 | 0.88 | GLP1R (0.57) | KISS1RNPY2RGLP1RSCTRVIPR1 | |
| SCHEMBL30676227 | 0.87 | NPY4R (0.46) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29684563 | 0.87 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL17887897 | 0.86 | NPY4R (0.61) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL17887995 | 0.86 | NPY4R (0.61) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31627888 | 0.86 | GLP1R (0.53) | GLP1RSCTRKEAP1VIPR2 | |
| SCHEMBL31516403 | 0.85 | GLP1R (0.49) | GLP1RSCTRKEAP1VIPR1VIPR2 | |
| SCHEMBL29519563 | 0.85 | OPRM1 (0.50) | KISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL31474484 | 0.85 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL29808185 | 0.85 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709750-A1 | BISPECIFIC ANTI-PSEUDOMONAS ANTIBODIES WITH MODIFIED FC REGIONS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024231440-A1 | BISPECIFIC ANTI-PSEUDOMONAS ANTIBODIES WITH MODIFIED FC REGIONS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | WO | disclosed |
| US-20240124612-A1 | MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES | MEDIMMUNE LLC | 2024-04-18 | — | — | US | disclosed |
| US-11767369-B2 | Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties | MEDIMMUNE, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| CN-106413750-B | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties | 免疫医疗有限责任公司 | 2022-04-29 | — | — | CN | disclosed |